Core Viewpoint - The article discusses various recent developments in different companies and industries, highlighting regulatory actions, legal disputes, financial performance, and strategic changes. Group 1: Regulatory Actions and Legal Issues - Five government departments have interviewed major food delivery platforms like JD.com, Meituan, and Ele.me regarding competition issues, urging them to comply with relevant laws and ensure fair competition [2] - Dior has reported a data breach affecting customer information, prompting the company to take immediate measures to control the situation and advise customers to be cautious [2] - Xiaomi won a lawsuit against Juhao Technology for defamation, resulting in a compensation of 550,000 yuan and a requirement for Juhao to publish a statement to mitigate the impact [3][4] Group 2: Company Financial Performance - JD Group reported a revenue of 301.1 billion yuan for Q1 2025, a year-on-year increase of 15.8%, with a net profit of 10.9 billion yuan compared to 7.1 billion yuan in Q1 2024 [10] Group 3: Corporate Restructuring and Strategic Changes - Zeekr announced that it has not made any decisions regarding the privatization proposal from its parent company Geely, which currently holds approximately 65.7% of Zeekr's shares [7] - Honor has established a new AI division and implemented a competitive recruitment process for key positions in China, with 45% of the positions seeing changes [9] - Nissan plans to reduce its production facilities from 17 to 10 by the 2027 fiscal year and aims to cut 20,000 jobs as part of a restructuring plan [16] Group 4: Market Trends and Product Launches - Toyota's new car sales in China increased by 20.8% in April, while Honda and Nissan experienced declines of 40.8% and 15.7%, respectively [22] - Samsung officially launched the Galaxy S25 Edge, starting at a price of 7,999 yuan, featuring advanced imaging capabilities and AI integration [20]

5月7日，汉邦科技科创板IPO进入申购阶段，申购代码为787755，申购价格为每股22.77元。 汉邦科技主营业务为制药、生命科学等领域提供专业的分离纯化装备、耗材与技术服务。公司主要产品 按类型可分为小分子药物分离纯化设备、大分子药物分离纯化设备等，可广泛应用于工业生产和实验室 研发的各类应用场景中。 小分子药物分离纯化装备主要为液相色谱设备，根据沙利文数据，2023年我国液相色谱设备(包含生产 级和实验室级)总规模超过27亿元，其中汉邦科技凭借在生产级液相色谱分离设备市场的快速增长排名 第二，市场份额约12.7%。同时如果只看生产级设备，根据沙利文数据，2023年汉邦科技市场占有率达 39.2%，排名第一。 值得一提的是，汉邦科技客户主要集中于境内，相较于境外竞争对手，汉邦科技在地域上更接近客户， 能够更全面、更迅速地提供技术支持和解决方案。此外，汉邦科技建立了完善的客户服务团队，可实时 了解客户需求，根据客户的问题随时制定相应解决方案，以保障客户生产线的尽快建立和稳定持续运 行。在销售方面，汉邦科技团队与客户也长期保持紧密合作的关系，参与客户方案的研发，随时听取客 户对产品的反馈意见，及时响应并解决客户 ...

招股书披露，汉邦科技是一家以色谱技术为核心，集研发、生产和销售于一体的高新技术企业，主要为制药、生命科学等领域提供专业的分离纯化装备、耗 材、应用技术服务及相关的技术解决方案。 5月7日，汉邦科技(688755.SH)开启申购，发行价格为22.77元/股，申购上限为0.5万股，市盈率26.35倍，属于上交所，中信证券为其保荐人。 汉邦科技产品和技术广泛应用于抗体、重组蛋白、疫苗、胰岛素、多肽、造影剂、抗生素等药物和天然产物的研发和生产。公司主要产品按类型可分为小分 子药物分离纯化设备、大分子药物分离纯化设备等，可广泛应用于工业生产和实验室研发的各类应用场景中。 | 项目 | | 2024年1-6月 | | 2023 年度 | | 2022 年度 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 产品 大类 | 产品小类 | 金额 | 足球 | 金额 | 日比 | 金额 | 早 | | | | 生产级小分 子药物分离 | 19.244.47 | 58.54% | 30.500.08 | 49.33% | 20,088.50 | 41. ...

Summary of Key Points Core Viewpoint - This week, three new stocks are available for subscription in the A-share market, including Hanbang Technology, Weigao Blood Purification, and Taili Technology [1][2]. Group 1: Hanbang Technology - Hanbang Technology is a leading company in chromatography equipment in China, with a subscription code of 787755 and an issue price of 22.77 yuan per share, with a P/E ratio of 26.35 times [3][6]. - The total number of shares issued is 22 million, with 5.28 million shares available for online subscription. The maximum subscription limit for investors is 5,000 shares, requiring a market value of 50,000 yuan in the Shanghai market [3][6]. - The company’s revenue is projected to grow from 482 million yuan in 2022 to 691 million yuan in 2024, with net profits increasing from 38.56 million yuan to 79.34 million yuan during the same period [7][10]. - Major clients include domestic pharmaceutical companies and international clients such as INTECH ANALYTICAL INSTRUMENTS and REETEC AS [7]. Group 2: Weigao Blood Purification - Weigao Blood Purification is a manufacturer of medical products for blood purification, with a subscription code of 732014. The total number of shares issued is 41.14 million, with 11.11 million shares available for online subscription [12][14]. - The company’s revenue is expected to rise from 3.426 billion yuan in 2022 to 3.604 billion yuan in 2024, with net profits increasing from 315.00 million yuan to 449.39 million yuan [12][14]. - Key clients include major pharmaceutical groups such as China National Pharmaceutical Group and China Resources Group [12]. Group 3: Taili Technology - Taili Technology focuses on new material research and vacuum technology applications, with a subscription code of 301595. The total number of shares issued is 27.07 million, with 6.90 million shares available for online subscription [17]. - The company’s revenue is projected to grow from 638 million yuan in 2022 to 1.020 billion yuan in 2024, with net profits increasing from 58.84 million yuan to 87.64 million yuan [17][18]. - Major clients include international retailers such as IKEA and Walmart, with Taili Technology being the exclusive supplier of vacuum bags for China's aerospace applications [17].

近年来，中国色谱市场正经历明显的"冰火两重天"局面：一方面，国内市场持续疲软，市场竞争日益激烈，中小企业生存承压；另一方面，国 产替代浪潮加速，头部企业融资频获突破，技术应用场景持续深化。在此背景下， ACCSI 2 0 2 5色谱新应用场景及产业生态升级发展论坛 将于 2 0 2 5年5月1 2日下午 在上海松江区富悦大酒店召开。论坛将汇聚行业领军者、顶级专家及产业链上下游代表，共同探讨中国色谱技术突围路径 与市场机遇。 点击报名参会 核心亮点抢先看 亮点一 聚焦细分市场突围，解码国产替代行业机遇 在中美关税战升级与政策强驱动下，色谱下游应用行业对降本增效、国产设备的迫切需求成为关键推力。特别是主流应用市场——制药与石化 领域成为破局关键。论坛将深度解析细分市场动态，邀请业内权威专家结合政策红利与行业痛点，探讨行业应用现状于需求，探讨国产色谱如 何从实现大市场的"国产替代"。 导读： 聚焦色谱技术，探讨国产替代机遇与产业升级路径，共话行业发展新趋势。ACCSI 2025色谱新应用场景及产业生态升级发展论坛将于2025年5月12日下午 在上海松江区富悦大酒店召开。 特别提示 微信公众号机制调整，请点击顶部"仪 ...